

## TRADEMARK ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Saviet Pharmaceuticals Inc.		05/09/2012	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	U.S. Bank National Association		
Street Address:	21 South Street, 3rd Floor		
City:	Morristown		
State/Country:	NEW JERSEY		
Postal Code:	07960		
Entity Type:	National Association: UNITED STATES		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	2948516	SAVIENT	
Registration Number:	3944590	SAVIENT	
Registration Number:	3920201	KRYSTEXXA	
Registration Number:	1754811	OXANDRIN	
Registration Number:	2184089	OXANDRIN	
CORRESPONDENCE DATA			
Fax Number:	2126561342		
	<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	212-318-6493		
Email:	david.adams@thomsonreuters.com		
Correspondent Name:	Robin Riley		
Address Line 1:	75 East 55th Street		
Address Line 2:	Paul Hastings LLP		
Address Line 4:	New York, NEW YORK 10022		

OP \$140.00 2948516

NAME OF SUBMITTER:	Robin Riley
Signature:	/david adams TR/
Date:	06/12/2012
<b>Total Attachments: 9</b> source=Savient Pharmaceuticals Trademark Cover Page executed#page1.tif source=Savient Pharmaceuticals IP Security Agmt#page1.tif source=Savient Pharmaceuticals IP Security Agmt#page2.tif source=Savient Pharmaceuticals IP Security Agmt#page3.tif source=Savient Pharmaceuticals IP Security Agmt#page4.tif source=Savient Pharmaceuticals IP Security Agmt#page5.tif source=Savient Pharmaceuticals IP Security Agmt#page6.tif source=Savient Pharmaceuticals IP Security Agmt#page7.tif source=Savient Pharmaceuticals IP Security Agmt#page8.tif	

### RECORDATION FORM COVER SHEET TRADEMARKS ONLY

To the Director of the U. S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

**1. Name of conveying party(ies):**

Savient Pharmaceuticals, Inc.

- Individual(s)
- General Partnership
- Corporation- State: Delaware
- Other \_\_\_\_\_
- Association
- Limited Partnership

Citizenship (see guidelines) \_\_\_\_\_

Additional names of conveying parties attached?  Yes  No

**2. Name and address of receiving party(ies)**

Additional names, addresses, or citizenship attached?  Yes  No

Name: U.S. Bank National Association

Internal

Address: 21 South Street, 3rd Floor

Street Address: \_\_\_\_\_

City: Morristown

State: New Jersey

Country: USA Zip: 07960

- Association Citizenship USA
- General Partnership Citizenship \_\_\_\_\_
- Limited Partnership Citizenship \_\_\_\_\_
- Corporation Citizenship \_\_\_\_\_
- Other \_\_\_\_\_ Citizenship \_\_\_\_\_

If assignee is not domiciled in the United States, a domestic representative designation is attached:  Yes  No  
(Designations must be a separate document from assignment)

**3. Nature of conveyance /Execution Date(s) :**

Execution Date(s) May 9, 2012

- Assignment
- Security Agreement
- Other \_\_\_\_\_
- Merger
- Change of Name

**4. Application number(s) or registration number(s) and identification or description of the Trademark.**

A. Trademark Application No.(s)

See attached Schedule I.

B. Trademark Registration No.(s)

See attached Schedule I.

Additional sheet(s) attached?  Yes  No

C. Identification or Description of Trademark(s) (and Filing Date if Application or Registration Number is unknown):

**5. Name & address of party to whom correspondence concerning document should be mailed:**

Name: Robin Riley

Internal Address: Paul Hastings LLP

Street Address: 75 East 55th Street

City: New York

State: NY Zip: 10022

Phone Number: 212-318-6493

Fax Number: 212-319-4090

Email Address: robinriley@paulhastings.com

**6. Total number of applications and registrations involved:**

5

**7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$**

- Authorized to be charged to deposit account
- Enclosed

**8. Payment Information:**

Deposit Account Number \_\_\_\_\_

Authorized User Name \_\_\_\_\_

**9. Signature:**

*Robin Riley*  
Signature

June 1, 2012

Date

Robin Riley

Name of Person Signing

Total number of pages including cover sheet, attachments, and document:

9

**INTELLECTUAL PROPERTY SECURITY AGREEMENT**

INTELLECTUAL PROPERTY SECURITY AGREEMENT dated as of May 9, 2012, by SAVIENT PHARMACEUTICALS, INC., a Delaware Corporation (the “**Grantor**”), in favor of U.S. BANK NATIONAL ASSOCIATION (the “**Collateral Agent**”).

WHEREAS, pursuant to that certain Pledge and Security Agreement, of even date herewith (as amended, restated, supplemented or otherwise modified from time to time, the “**Security Agreement**”), among the Grantor, the Collateral Agent and certain other parties thereto, in order to secure payments of certain Secured Obligations (as defined in the Security Agreement), the Grantor hereby assigns, pledges and grants to the Collateral Agent a continuing security interest in and to all of the Collateral whether now owned or hereinafter acquired and whether now existing or hereafter arising (as defined in the Security Agreement) including, without limitation, the trademarks and trademark applications listed on Schedule I hereto and the patents listed on Schedule II hereto (the “**Intellectual Property**”). Until all of the Secured Obligations have been indefeasibly paid in full, the Collateral Agent shall retain its security interest in the Intellectual Property granted herein and in the Security Agreement.

NOW, THEREFORE, for the consideration set forth herein and in the Security Agreement, the parties hereby agree that the Grantor, as collateral security for the full, prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of its Secured Obligations under the Security Agreement, hereby grants the Collateral Agent a lien on and security interest in, all of its right, title and interest in, to and under the Intellectual Property (including (i) all reissues, continuations, renewals or extensions of the foregoing, (ii) all goodwill of the business connected with the use of, and symbolized by, each Intellectual Property, and (iii) all products and proceeds of the foregoing).

FOR THE AVOIDANCE OF DOUBT, notwithstanding any other provision of this agreement, the Grantor does not grant any lien on or security interest in any of the Excluded Assets (as defined in the Security Agreement).

[Signature Pages Follow]

IN WITNESS WHEREOF, Loan Party has caused this INTELLECTUAL PROPERTY SECURITY AGREEMENT to be executed and delivered by its duly authorized officer as of the date first set forth above.

SAWENT PHARMACEUTICALS, INC.

By: 

Name: Philip K. Yachmetz

Title: Senior Vice President, General Counsel & Secretary

[IP SECURITY AGREEMENT]

TRADEMARK  
REEL: 004799 FRAME: 0890

ACCEPTED AND ACKNOWLEDGED BY:

U.S. BANK NATIONAL ASSOCIATION

By: 

Name: *R. J. Bowers*

Title: *Vice President*

[IF SECURITY AGREEMENT]

**Schedule I  
Trademarks**

*U.S. Trademark Registrations*

Registrant: Savient Pharmaceuticals, Inc.

<b>Mark</b>	<b>Registration No.</b>	<b>Registration Date</b>
SAVIENT	2,948,516 (Serial No. 76/230,848)	5/10/2005
SAVIENT	3,944,590 (Serial No. 77/266,837)	4/12/2011
KRYSTEXXA	3,920,201 (Serial No. 77/552,516)	2/15/2011
OXANDRIN	1,754,811 (Serial No. 74/215,022)	3/2/1993
OXANDRIN	2,184,089 (Serial No. 75/344,954)	8/25/1998

*U.S. Trademark Applications*

Applicant: Savient Pharmaceuticals, Inc.

<b>Mark</b>	<b>Application No.</b>	<b>Filing Date</b>
N/A		

*State Trademark Registrations*

Registrant: Savient Pharmaceuticals, Inc.

<b>Mark</b>	<b>State</b>	<b>Registration No.</b>	<b>Registration Date.</b>
N/A			

**Schedule II  
Patents**

<b>Owner</b>	<b>Patent No.</b>	<b>Issued Date</b>	<b>Description</b>
Savient/Duke University	US Pat 8,148,123	issued 4/3/12	METHODS FOR LOWERING ELEVATED URIC ACID LEVELS
Savient	US Pat 7,811,800	issued 10/12/10	VARIANT FORM OF URATE OXIDASE
Savient	US Pat 7,964,381	issued 6/21/11	VARIANT FORM OF URATE OXIDASE
Savient	US Pat 8,034,594	issued 10/1/11	VARIANT FORM OF URATE OXIDASE
Savient	US Pat 8,178,334	issued 5/15/12	VARIANT FORM OF URATE OXIDASE AND USE THEREOF
Savient	US Pat 8,188,224	issued 5/29/12	VARIANT FORM OF URATE OXIDASE AND USE THEREOF
Savient	US Pat 8,053,425		USE OF OXANDROLONE IN THE TREATMENT OF BURNS AND OTHER WOUNDS
Savient	US Pat 8,026,274		USE OF OXANDROLONE IN THE TREATMENT OF BURNS AND OTHER WOUNDS
Savient	US Pat 7,087,722	issued 8/8/06	FIBRIN BINDING DOMAIN POLYPEPTIDES AND USES AND METHODS OF PRODUCING SAME
Savient	US Pat 6,828,313	issued 12/7/04	USE OF OXANDRONE IN THE TREATMENT OF BURNS AND OTHER WOUNDS
Savient	US Pat 6,670,351	issued 12/30/03	METHOD FOR AMELIORATING MUSCLE WEAKNESS/WASTING IN A PATIENT INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1
Savient	US Pat 6,610,520	issued 8/26/03	HUMAN MANGANESE SUPEROXIDE DISMUTASE DNA, ITS EXPRESSION AND METHOD OF RECOVERING HUMAN MANGANESE SUPEROXIDE DISMUTASE
Savient	US Pat 6,576,659	issued 6/10/03	USE OF OXANDROLONE IN THE TREATMENT OF BURNS AND OTHER WOUNDS
Savient	US Pat 6,361,772	issued 3/26/02	HUMAN MANGANESE SUPEROXIDE DISMUTASE DNA, ITS EXPRESSION AND METHOD OF RECOVERING HUMAN MANGANESE SUPEROXIDE DISMUTASE
Savient	US Pat 6,121,426	issued 9/19/00	FIBRIN BINDING DOMAIN POLYPEPTIDES AND USES AND METHODS OF PRODUCING SAME
Savient	US Pat 6,090,799	issued 7/18/00	METHOD FOR AMELIORATING MUSCLE WEAKNESS/WASTING IN A PATIENT INFECTED WITH



Savient	US Pat 6,054,291	issued 4/25/00	HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 EXPRESSION VECTORS FOR ENHANCED PRODUCTION OF POLYPEPTIDES, PLASMIDS CONTAINING THE VECTORS, HOST CONTAINING THE PLASMIDS, PRODUCTS MANUFACTURED THEREBY AND RELATED METHODS
Savient	US Pat 6,030,611	issued 2/29/00	PLASMIDS FOR EXPRESSION OF HUMAN SUPEROXIDE DISMUTASE (SOD) ANALOGS CONTAINING LAMDA PL PROMOTER WITH ENGINEERED RESTRICTION SITE FOR SUBSTITUTING RIBOSOMAL BINDING SITES, SOD ANALOGS, METHODS OF RECOVERY AND USES THEREOF
Savient	US Pat 6,010,875	issued 1/4/00	EXPRESSION PLASMIDS CONTAINING THE DEO PROMOTER, AND BACTERIAL HOSTS CONTAINING THE PLASMIDS
Savient	US Pat 6,001,604	issued 12/14/99	REFOLDING OF PROINSULINS WITHOUT ADDITION OF REDUCING AGENTS
Savient	US Pat 5,965,383	issued 10/12/99	FIBRIN BINDING DOMAIN POLYPEPTIDES AND USES AND METHODS OF PRODUCING SAME
Savient	US Pat 5,948,668	issued 9/7/99	PRODUCTION OF ENZYMATICALLY ACTIVE RECOMBINANT CARBOXYPEPTIDASE B
Savient	US Pat 5,945,304	issued 8/31/99	EXPRESSION PLASMIDS REGULATED BY AN OSMB PROMOTER
Savient	US Pat 5,872,147	issued 2/16/99	USE OF OXANDROLONE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Savient	US Pat 5,869,616	issued 2/9/99	FIBRIN BINDING DOMAIN POLYPEPTIDES AND USES AND METHODS OF PRODUCING SAME
Savient	US Pat 5,795,776	issued 8/18/98	EXPRESSION PLASMIDS REGULATED BY AN OSMB PROMOTER
Savient	US Pat 5,763,215	issued 6/9/98	METHOD OF REMOVING N-TERMINAL AMINO ACID RESIDUES FROM EUKARYOTIC POLYPEPTIDE ANALOGS AND POLYPEPTIDES PRODUCED THEREBY
Savient	US Pat 5,759,816	issued 6/2/98	EXPRESSION VECTORS CONTAINING LAMBDA PL PROMOTER AND T1 T2 RRNA TERMINATION SEQUENCE PLASMIDS CONTAINING THE

Savient	US Pat 5,679,320	issued 10/21/97	VECTORS HOSTS CONTAINING THE PLASMIDS AND RELATED METHODS
Savient	US Pat 5,670,371	issued 9/23/97	FIBRIN BINDING DOMAIN POLYPEPTIDES AND USES AND METHODS OF PRODUCING SAME
Savient	US Pat 5,637,495	issued 6/10/97	BACTERIAL EXPRESSION OF SUPEROXIDE DISMUTASE PLASMIDS FOR PRODUCTION OF HUMAN GROWTH HORMONE OR POLYPEPTIDE ANALOG THEREOF, HOSTS CONTAINING THE PLASMIDS, PRODUCTS MANUFACTURED THEREBY, AND RELATED METHODS
Savient	US Pat 5,593,860	issued 1/14/97	EXPRESSION PLASMIDS CONTAINING THE DEO PROMOTER, AND BACTERIAL HOSTS CONTAINING THE PLASMIDS
Savient	US Pat 5,540,911	issued 7/30/96	METHODS OF USE OF HUMAN MANGANESE SUPEROXIDE DISMUTASE
Savient	US Pat 5,455,158	issued 10/3/95	FIBRIN BINDING DOMAIN POLYPEPTIDES AND USES AND METHODS OF PRODUCING SAME
Savient	US Pat 5,360,729	issued 11/1/94	METHOD FOR PURIFICATION OF RECOMBINANT COPPER/ZINC (CU-ZN) SUPEROXIDE DISMUTASE FROM BACTERIA OR EUKARYOTIC CELLS
Savient	US Pat 5,270,195	issued 12/14/93	PLASMIDS FOR EXPRESSION AND METHOD OF PRODUCING A HUMAN MANGANESE SUPEROXIDE DISMUTASE ANALOG
Savient	US Pat RE35724	issued 2/3/98	CONTRACEPTION SYSTEM AND METHOD

### Patent Applications

Owner	Application No.	Filing Date	Description
Savient	US Prov 60/670,573	filed 4/11/05, exp. 4/11/06	VARIANT FORMS OF URATE OXIDASE
Savient	PCT/US06/13660	filed 4/11/06	VARIANT FORMS OF URATE OXIDASE
Savient	WO 2006/110819		
Savient	US App 11/918,297	filed 10/10/07	VARIANT FORMS OF URATE OXIDASE
Savient/Duke University	US 2009/0169534		
Savient/Duke University	US App 11/899,688	filed 9/7/07	METHODS FOR LOWERING ELEVATED URIC ACID LEVELS
Savient	US 2008/0159976		
Savient	US Prov 60/670,541	filed 4/11/05, exp. 4/11/06	VARIANT FORM OF URATE OXIDASE
Savient	PCT/US06/13502	filed 4/11/06	VARIANT FORM OF URATE OXIDASE
Savient	WO/2006/110761		

Savient	US App 13/452,151	filed 4/20/12	VARIANT FORM OF URATE OXIDASE
Savient	US App 13/461,170	filed 5/1/2012	VARIANT FORM OF URATE OXIDASE
Savient	US Prov 60/670,520	filed 4/11/05, exp. 4/11/06	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT
Savient	PCT/US06/13751 WO/2008/051178	filed 4/12/06	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT
Savient	US App 11/918,292 US 2009/0317889	filed 10/11/07	PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT
Savient	US Prov 61/248,680	filed 10/5/09, exp. 10/5/10	DEVELOPMENTS RELATED TO THE TREATMENT OF GOUT
Savient	US Prov 61/269,669	filed 6/25/09, exp. 6/25/09	DEVELOPMENTS RELATED TO THE TREATMENT OF GOUT
Savient	US Prov 61/248,698	filed 10/5/09, exp. 10/5/10	DEVELOPMENTS RELATED TO THE TREATMENT OF GOUT
Savient	US Prov 61/261,589	filed 11/16/09, exp. 11/16/10	DEVELOPMENTS RELATED TO THE TREATMENT OF GOUT
Savient	US Prov 61/298,718	filed 1/27/10, exp. 1/27/11	DEVELOPMENTS RELATED TO THE TREATMENT OF GOUT
Savient	PCT/US10/400093 WO10/151831	filed 6/25/10	DEVELOPMENTS RELATED TO THE TREATMENT OF GOUT
Savient	PCT/US10/40082 WO 10/151823	filed 6/25/10	DEVELOPMENTS RELATED TO THE TREATMENT OF GOUT
Savient	US App 13/379,719	filed 12/21/11	DEVELOPMENTS RELATED TO THE TREATMENT OF GOUT
Savient	US App 60/932,649	filed 6/1/07, exp. 6/1/08	
Savient	US App 13/379,704	filed 12/21/11	DEVELOPMENTS RELATED TO THE TREATMENT OF GOUT
Savient	US 2012/0070876		VARIANT FORM OF URATE OXIDASE AND USE THEREOF
Savient	US 2012/0015875		USE OF OXANDROLONE IN THE TREATMENT OF BURNS AND OTHER WOUNDS
Savient	US 2011/0217755		VARIANT FORM OF URATE OXIDASE AND USE THEREOF
Savient	US 2011/0104751		VARIANT FORM OF URATE OXIDASE AND USE THEREOF
Savient	US 2007/0254029		METHOD OF AMELIORATING MUSCLE WEAKNESS/WASTING IN A PATIENT INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
Savient	US App 10/052,961 US 2002/0091155	filed 1/18/02	METHOD OF AMELIORATING MUSCLE WEAKNESS/WASTING IN A PATIENT INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1